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Background & Aim: 
• Catheter-related sepsis remains a significant threat to preterm babies in the neonatal intensive care unit (NICU)
• Evidence is lacking about the optimal skin disinfection to be used for catheterisation in preterm infants
• We aimed to conduct a feasibility study to inform the design of a definitive randomised controlled trial (RCT) to
investigate the safety and efficacy of alcohol-based vs. aqueous-based 2% Chlorhexidine Gluconate (CHG) antiseptic
formulations for skin disinfection prior to percutaneous central venous catheter (PCVC) insertion
Methods:
• We conducted a masked feasibility RCT in two tertiary-level neonatal intensive care units (ISRCTN: 82571474)
• We randomised infants born <34 weeks’ gestation, and due to undergo PCVC insertion, to receive in a 3:1 ratio either
2%CHG-70% isopropyl alcohol (IPA) or 2%CHG-aqueous for skin antisepsis prior to catheter insertion
• Our feasibility study outcomes included rates of: i) recruitment and retention; ii) data completeness; iii) catheter
colonisation, catheter-related sepsis (CRS), catheter- associated sepsis (CAS), and CRS/CAS per 1,000 PCVC days. Safety
outcomes were daily skin morbidity scored using a validated neonatal skin scoring system, and recorded from catheter
insertion until 48h post-removal
• Primary clinical outcome was the proportion of infants in the 2%CHG-70%IPA arm with catheter colonisation at the time
of catheter removal. Target sample size was at least 93 infants with successful PCVC insertion based upon an anticipated
20% incidence of PCVC colonisation in the reference 2%CHG-70%IPA group (estimated with 95% confidence interval (CI)
11% to 31%)
• The Trial Protocol http://www/npeu.ox.ac.uk/arctic and further details of the methodology are published [1]
Results: 
• 116 (65.2%) of 178 eligible infants were recruited and
randomised. 88 (76%) were allocated to 2%CHG-70%IPA group
• Overall, 51.7% were boys, median (IQR) gestation at birth was
28 (26-30) wks, and median (IQR) age at catheterisation was 5
days (2-7 days); 40% catheters were inserted <3 days postnatal
and 22% insertions were in babies <26 weeks GA. Postnatal age
at catheter removal was on median day 14 (IQR: 10-20 days).
• 97 (84.1%) included infants completed the study. Rates of
recruitment, retention and data completeness were good
• Primary outcome incidence was 4.1% (95% CI: 0.9%, 11.5%);
overall catheter colonisation rate was 5.2% (5/97); CRS
2.3/1,000 catheter days; CAS 14.8/1,000 catheter days (Table)
• No significant antiseptic-related skin injury was reported
Conclusions: 
• The ARCTIC study provides preliminary reassurance regarding safe use of 2%CHG aqueous and 2%CHG-70%IPA in 
preterm neonates for skin disinfection prior to percutaneous central venous catheterisation
• A definitive trial is feasible, but the very low catheter colonisation rate in the reference 2%CHG-70%IPA group 
indicates that a very large sample size would be required (approx. 3,500 babies for a non inferiority trial)
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